This company seems to have been delisted
Reason: Acquired by Carlyle and SK Capital
Source: https://www.fiercepharma.com/pharma/once-valued-10b-bluebird-bio-sells-private-equity-firms-29m
Reason: Acquired by Carlyle and SK Capital
Source: https://www.fiercepharma.com/pharma/once-valued-10b-bluebird-bio-sells-private-equity-firms-29m
bluebird bio
BLUE
£3.70
Share price
0.00%
Change (1 day)
-76.48%
Change (1 year)
bluebird bio (BLUE) - Total debt
Total debt on the balance sheet as of March 2025 : £0.14 Billion
According to bluebird bio 's latest financial reports the company's total debt is £0.14 Billion. A company’s total debt is the sum of all current and non-current debts.
bluebird bio - Total debt on balance sheet (from 2015 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | £0.28 B | 9.01% |
| 2023-12-31 | £0.26 B | -13.69% |
| 2022-12-31 | £0.30 B | 357.16% |
| 2021-12-31 | £66.36 M | 38.28% |
| 2020-12-31 | £47.99 M | -67.05% |
| 2019-12-31 | £0.14 B | 19.47% |
| 2018-12-31 | £0.12 B | 5.75% |
| 2017-12-31 | £0.11 B | 18.4% |
| 2016-12-31 | £97.36 M | 133.1% |
| 2015-12-31 | £41.77 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 BioMarin Pharmaceutical BMRN | £0.44 B | 219.95% | 🇺🇸 USA |
 Acceleron Pharma XLRN | N/A | N/A | 🇺🇸 USA |
 Sanofi SNY | £16.95 B | 12,002.70% | 🇫🇷 France |
 Sangamo Therapeutics
SGMO | £18.51 M | -86.78% | 🇺🇸 USA |
 Merck MRK | £25.93 B | 18,419.86% | 🇺🇸 USA |
 GlycoMimetics
GLYC | N/A | N/A | 🇺🇸 USA |